FDA panel votes 3-14 that Abbott (ABT) has not found right Humira dose
- Stock futures lower as countdown to Yellen speech begins
- Mylan's (MYL) Steps on EpiPen Do Not Go Far Enough - Wells Fargo's Maris
- Amazon (AMZN) Announces Car Research Destination Amazon Vehicles
- Bank of America (BAC) at an Inflection Point - Goldman Sachs
- Valeant (VRX) Management Meeting Reinforces Confidence - Morgan Stanley
FDA panel votes 3-14 that Abbott (NYSE: ABT) has not found right Humira dose.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbott to Present at Wells Fargo Healthcare Conference
- Mallinckrodt (MNK) Granted FDA Fast Track Designation for Synacthen IND as DMD Treatment
- Impax Laboratories (IPXL) and Teva Pharma (TEVA) Seen as Beneficiaries of Mylan's (MYL) EpiPen Woes - RBC
Create E-mail Alert Related CategoriesFDA, General News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!